Skip to main content
. 2016 Aug 1;7(36):58142–58147. doi: 10.18632/oncotarget.10983

Figure 2. OTX015 levels in plasma and tumor tissue of SUDHL2-tumor bearing mice as a single agent or in combination with other agents.

Figure 2

A. Plasma and B. tissue levels of OTX015 (oral 50 mg/kg/day) were measured after 5 weeks treatment, 4 h after the last OTX015 administration. Each bar represents the mean ± standard deviation.